Острые лейкозы

Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML.

In the past decades, treatment for acute myeloid leukemia (AML) has advanced, but allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains vital for improving survival in most patients...

DOI: 10.1038/s41409-025-02614-1
Dachy G, Labopin M, Socié G, Castilla-Llorente C, Forcade E, Blau IW, Ceballos P, Deconinck E, Burns D, Bulabois CE, Vrhovac R, Huynh A, Blaise D, Maertens J, Schroeder T, Bay JO, Savani B, Spyridonidis A, Ciceri F, Mohty M
Bone marrow transplantation, 2025-06-21

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.

Inflammation is increasingly recognized as a critical factor in acute myeloid leukemia (AML) pathogenesis...

DOI: 10.1182/blood.2024027244
Reville PK, Wang B, Marvin-Peek J, Yuan B, Kuo YA, Garza A, Root J, Qiao W, Arruda A, Veletic I, Liu Y, Short NJ, DiNardo CD, Kadia TM, Daver NG, Lorenzi PL, Sasaki K, Kornblau S, Minden MD, Ravandi F, Kantarjian HM, Abbas HA
Blood, 2025-06-21

Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible regardless of social determinants of health (SDOH) remains unknown...

DOI: 10.1182/blood.2024027543
Wuliji N, Jones SMW, Gooley T, Gerds AT, Medeiros BC, Shami PJ, Galvin J, Adekola K, Luger S, Baer MR, Rizzieri D, Wildes TM, Wang ES, Sekeres MA, Mukherjee S, Smith J, Garrison M, Kojouri K, Appelbaum J, Percival ME, Sandmaier BM, Lee S, Appelbaum F
Blood, 2025-06-21